i saw this on another forum and thought it worth posting here as i know there are alot of members who have either suspected or confirmed lyme and bart -
its pretty long - even though just a summary of some of his reccent trials - but the spoiler is he is showing a significant number of his sickest patients - even those that fail double dapsone therapy - are getting better with several rounds of even higher dose dapsone - pulsed for a few days at a time
--______________________--
I would like to offer a gift to the Lyme disease community for May, Lyme Awareness month. As many of you know, I have been searching for short, safe and effective treatments for Lyme disease and associated co-infections for over 30 years. Dr Freeman and I worked feverishly over the last 5-6 weeks to submit an article to the journal Microorganisms, for their special issue on Ticks and Tick-borne Infections:
Horowitz, R.I.; Freeman, P.R. Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Literature Review. Preprints 2022, 2022040296 (doi: 10.20944/preprints202204.0296.v1).
https://www.preprints.org/manuscript
/202204.0296/v1
This treatment regimen, which needs to be replicated in large controlled trials, potentially represents a major advance in the treatment of Lyme and associated TBD's. Treatment using pulsed high dose dapsone combination therapy (HDDCT, 4 day pulses) illustrates that it is not only the length of time on persister drugs like DSF and dapsone, but it is also the DOSE that is critically important. Please take the time to read the three case studies and 25 patients who did this treatment protocol. These were highly resistant tickborne cases who had multiple abnormalities on the 16 point MSIDS map, including chronic babesiosis and Bartonellosis. Many of these chronically ill patients, even if they had some benefit from dapsone combination therapy in the past, had failed to achieve remission with 8 weeks of double dose dapsone combination therapy (DDDCT). We found that 8/25 patients achieved remission for three months or longer with one to three pulses of HDDCT (4 -8 day regimens), including several who were Bartonella FISH positive.
"Treatment results: Twenty-one of 25 patients (84 %) showed improvement of their tick-borne symptoms, and one patient had a temporary worsening of symptoms post therapy, secondary to a severe Herxheimer reaction. Thirty-two percent (8/25) had a resolution of all active Lyme symptoms post treatment for 3 months or longer even if there was evidence of prior active co-infections, including Babesia and Bartonella. Three out of 7 patients (43%) with an EM rash and history of PTLDS remained in remission, and the remainder, 57%, showed a mild-moderate improvement in underlying symptoms above their baseline functioning. Among 11 patients who were Babesia FISH positive, three (27 %) remained in remission, six improved (55%) and two (18%) had no change in sweats, chills, or flushing or dyspnea. Among 19 patients (76%) with a history of Bartonella exposure, 15/19 improved (79%), and four patients (21%) had no change in symptoms. Among 8 patients with proof of active Bartonella infection (PCR positive, FISH positive, and/or elevated VEGF), 3/8 (38%) remained in remission, and 5/8 (62%) improved their underlying symptomatology. Further examination of those patients revealed that among those who were Bartonella FISH positive, two out of four went into remission (50%) and the other two improved their underlying symptomatology by 10% to 20% above baseline functioning. The largest symptom improvement seen among this cohort treated with HDDCT were cognition 17/25 (68%), joint and muscle pain 16/25 (64%), fatigue 15/25 (60%), headache 9/25 (36%), neuropathy 5/25 (20%), insomnia 5/25 (20%), sweats/chills/flushing (20%), palpitations 2/25 (8%), tinnitus 2/25 (8%), dyspnea 1/25 (4%), and visual “snow” 1/25 (4%). "
As many of you know, there is no published 'cure' for chronic Bartonella. In the past, highly resistant Bartonella required either long term treatments with multiple intracellular antibiotics and/or use of medications like Gentamycin to achieve remission. This protocol uses oral, generic medication with excellent penetration into the CNS and was effective using short term, high dose pulses for patients who had failed prior protocols. This obviously needs to be confirmed in large, clinical trials, but having been in the field for over 30 years, I know when I have discovered something with great potential. It will up to clinicians in the field to replicate the study (the details are in the paper). I would suggest that the RCT that be performed, to answer the questions on CLD/PTLDS once and for all, is an 8 week double dose dapsone combination therapy regimen (DDDCT), and in those who fail to achieve remission (appx 50% based on prior published clinical studies) after all MSIDS variables have been addressed, is to have these patients undergo several rounds of high dose pulsed dapsone combination therapy (HDDCT) to evaluate response and remission rates.
This is also the first paper to be submitted to the scientific literature where two persister drugs were used simultaneously in a certain percentage of patients. In one patient, who did well with disulfiram (DSF) but failed to achieve remission, one 4 day pulse of HDDCT led to remission for 3 months or longer. This novel regimen potentially offers a brand new treatment approach for those who have failed long term oral and/or IV therapy. We still need however to find effective treatment regimens for babesia, which persisted in several patients (we are doing trials of tafenoquine now, read the paper) and we can't know the full long term results for Borrelia and Bartonella without longer term follow-up and performing this protocol in large numbers of chronically ill patients. That being said, this protocol helped certain very ill patients who were sick for decades.
Lyme community, governmental agencies, researchers: Please make sure we get a RCT performed on this protocol. It has the potential to answer many questions that have plagued the Lyme community for over 40 years. Having now published on over 340 patients who have done dapsone combination therapy, I can say with certainty, these persister drugs, dapsone and DSF, are a major advance for the Lyme and TBD community. And short term oral generic protocols with combination therapy offers potential answers while avoiding issues with antibiotic resistance. We now need to use scientific rigor to explore the use of these protocols, as it is described in the paper, in greater detail. This regimen is not without potential side effects however, and we explained in detail in the paper how we managed them effectively in our patient population. I will be doing my yearly training course for health care providers on Lyme and TBDS and the MSIDS model in early August of this year. For those practitioners who want to learn how to use this model in their chronically ill patients, and sign up for the training course, please contact Heather at:
[email protected]I am very excited to present this scientific investigation to the Lyme community for May, Lyme Awareness month. You have all been searching for durable cures and answers for your chronic illness. I have been doing my best to help you for over 30 years. I hope from the bottom of my heart, that this regimen of HDDCT and addressing MSIDS variables, will be part of the solution you have all been looking for.
Blessings,
Dr Richard Horowitz